Barbara Metch

2.1k total citations · 1 hit paper
21 papers, 1.6k citations indexed

About

Barbara Metch is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Barbara Metch has authored 21 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Barbara Metch's work include Breast Cancer Treatment Studies (5 papers), Head and Neck Cancer Studies (5 papers) and Cancer Treatment and Pharmacology (4 papers). Barbara Metch is often cited by papers focused on Breast Cancer Treatment Studies (5 papers), Head and Neck Cancer Studies (5 papers) and Cancer Treatment and Pharmacology (4 papers). Barbara Metch collaborates with scholars based in United States. Barbara Metch's co-authors include Dorit Elisabeth Schuller, John F. Ensley, Julie A. Kish, Arlene A. Forastiere, Stephen K. Williamson, Pierre L. Triozzi, Polly Feigl, Stephanie E. McClure, Laura F. Hutchins and Carol M. Moinpour and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Barbara Metch

21 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.

1992 550 citations Arlene A. Forastiere, Barbara Metch et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Barbara Metch

Since Specialization

Citations

This map shows the geographic impact of Barbara Metch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Metch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Metch more than expected).

Fields of papers citing papers by Barbara Metch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Metch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Metch. The network helps show where Barbara Metch may publish in the future.

Co-authorship network of co-authors of Barbara Metch

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Metch. A scholar is included among the top collaborators of Barbara Metch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara Metch. Barbara Metch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. 1994 ·Journal of Clinical Oncology ·Saul E. Rivkin, (unknown), Barbara Metch, Anatolio B. Cruz, Martin D. Abeloff, William R. Jewell, J J Costanzi, William B. Farrar, (unknown), C. Kent Osborne	82
2	Phase II Evaluation of Amonafide in Advanced Sarcoma: A Southwest Oncology Group Study 1994 ·Cancer Investigation ·Saundra S. Buys, Barbara Metch, Stanley P. Balcerzak, John R. Neefe, W. J. Stuckey	2
3	One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study. 1993 ·Journal of Clinical Oncology ·Saul E. Rivkin, (unknown), Barbara Metch, William R. Jewell, J J Costanzi, (unknown), (unknown), Robert M. OʼBryan, C. Kent Osborne	16
4	Pitfalls in quality-of-life assessment: lessons from a Southwest Oncology Group breast cancer clinical trial. 1993 ·PubMed ·(unknown), (unknown), Barbara Metch, Polly Feigl, (unknown), (unknown), (unknown)	19
5	Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. breakdown → 1992 ·Journal of Clinical Oncology ·Arlene A. Forastiere, Barbara Metch, Dorit Elisabeth Schuller, John F. Ensley, Laura F. Hutchins, Pierre L. Triozzi, Julie A. Kish, Stephanie E. McClure, (unknown), Stephen K. Williamson	550
6	A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma: A southwest oncology group study 1992 ·Cancer ·Bernard L. Zidar, Barbara Metch, Stanley P. Balcerzak, H. Irving Pierce, (unknown), (unknown), Jeffrey L. Berenberg	34
7	Adjuvant combination chemotherapy cmfvp vs oophorectomy followed by cmfvp ocmfvp for premenopausal women with er positive operable breast cancer with positive axillary lymph nodes an intergroup study 1991 ·Breast Cancer Research and Treatment ·Saul E. Rivkin, (unknown), Barbara Metch, (unknown), (unknown), John H. Glick, William S. Knight, C. Kent Osborne	7
8	Phase II Studies of Recombinant Human Tumor Necrosis Factor Alpha in Patients with Malignant Disease: A Summary of the Southwest Oncology Group Experience 1991 ·Journal of Immunotherapy ·Evan M. Hersh, Barbara Metch, Franco M. Muggia, Thomas D. Brown, Robert P. Whitehead, G. Thomas Budd, John J. Rinehart, E. David Crawford, John D. Bonnet, Brent C. Behrens	49
9	Phase III Comparison of Doxorubicin and Dacarbazine Given by Bolus Versus Infusion in Patients With Soft-Tissue Sarcomas: A Southwest Oncology Group Study 1991 ·JNCI Journal of the National Cancer Institute ·Mark M. Zalupski, Barbara Metch, S P Balcerzak, William S. Fletcher, Robert Chapman, John D. Bonnet, Geoffrey R. Weiss, J.F. Ryan, Robert S. Benjamin, Larry Baker	125
10	Phase II study of fazarabine in advanced head and neck cancer 1991 ·Investigational New Drugs ·J. Philip Kuebler, Barbara Metch, David E. Schuller, (unknown), Harry E. Hynes	8
11	Phase II Evaluation of Recombinant Interferon-β (LFN-β _ser ) in Patients with Diffuse Mesothelioma: A Southwest Oncology Group Study 1990 ·Journal of Interferon Research ·Daniel D. Von Hoff, Barbara Metch, Joel G. Lucas, Stanley P. Balcerzak, Steven M. Grunberg, Saul E. Rivkin	37
12	Phase II trial of echinomycin in advanced soft tissue sarcomas 1990 ·Investigational New Drugs ·Sarah A. Taylor, Barbara Metch, Stanley P. Balcerzak, (unknown)	8
13	High‐dose cisplatin for metastatic soft tissue sarcoma 1990 ·Cancer ·G. Thomas Budd, Barbara Metch, Stanley P. Balcerzak, William S. Fletcher, Laurence H. Baker, Joanne Mortimer	12
14	Analysis of Treatment Failure Patterns: A Southwest Oncology Group Study 1989 ·Archives of Otolaryngology - Head and Neck Surgery ·Dorit Elisabeth Schuller, (unknown), Barbara Metch	28
15	Quality of Life End Points in Cancer Clinical Trials: Review and Recommendations 1989 ·JNCI Journal of the National Cancer Institute ·Carol M. Moinpour, Polly Feigl, Barbara Metch, Katherine Hayden, F. L. Meyskens, John M. Crowley	311
16	Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study. 1989 ·Journal of Clinical Oncology ·Saul E. Rivkin, (unknown), Barbara Metch, Harold Glucksberg, (unknown), (unknown), Barth Hoogstraten, J. W. Athens, Thomas R. Maloney, C. Kent Osborne	33
17	Preoperative chemotherapy in advanced resectable head and neck cancer: Final report of the southwest oncology group 1988 ·The Laryngoscope ·David E. Schuller, (unknown), Barbara Metch, Douglas E. Mattox, Joseph D. McCracken	208
18	VP‐16 + adriamycin vs. Adriamycin alone in advanced adenocarcinoma of the breast, phase II, a randomized trial: A southwest oncology group study 1988 ·Medical and Pediatric Oncology ·Clarence B. Vaughn, Stephanie Green, Robert M. OʼBryan, Melvin L. Reed, P Grozea, William S. Fletcher, (unknown), Barbara Metch, Noboru Oishi	14
19	Platinum analogs in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University Study. 1987 ·PubMed ·Muhyi Al‐Sarraf, Barbara Metch, Julie A. Kish, John F. Ensley, (unknown), (unknown), Coltman Ca	52
20	Phase II trial of fludarabine phosphate in patients with head and neck cancer: a Southwest Oncology Group Study. 1987 ·PubMed ·(unknown), Barbara Metch, Von Hoff, (unknown), (unknown)	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact